Literature DB >> 1388078

Lipids and lipoproteins in persons with Down's syndrome.

S M Pueschel1, W Y Craig, J E Haddow.   

Abstract

This study was designed to investigate whether the observed decreased prevalence of coronary artery disease in individuals with Down's syndrome may be explained by their serum lipid and lipoprotein profiles. Twenty-seven persons with Down's syndrome and 23 non-affected control individuals were enrolled in this study. Their fasting venous blood was analysed for total cholesterol, triglyceride, LDH cholesterol, HDL cholesterol, apo B and apo AI. The results revealed no significant differences between the study and control group with regard to total cholesterol, LDL cholesterol, apo B and the apo B:apo AI ratio. However, triglyceride levels were significantly increased, and serum HDL cholesterol, apo AI and HDL cholesterol:total cholesterol ratio were significantly decreased in patients with Down's syndrome when compared with the control group. The latter observations are all associated with an increased risk for coronary artery disease. Therefore, it is concluded that the decreased prevalence of coronary artery disease in individuals with Down's syndrome cannot be explained by the lipid and lipoprotein levels observed in this study population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388078     DOI: 10.1111/j.1365-2788.1992.tb00535.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  14 in total

Review 1.  An overview and update regarding medical problems in Down syndrome.

Authors:  V Grech
Journal:  Indian J Pediatr       Date:  2001-09       Impact factor: 1.967

2.  Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins.

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

3.  Age-related changes in plasma levels of BDNF in Down syndrome patients.

Authors:  Giada Dogliotti; Emanuela Galliera; Federico Licastro; Massimiliano M Corsi
Journal:  Immun Ageing       Date:  2010-01-25       Impact factor: 6.400

4.  Cardiometabolic Risk and Body Composition in Youth With Down Syndrome.

Authors:  Sheela N Magge; Babette S Zemel; Mary E Pipan; Samuel S Gidding; Andrea Kelly
Journal:  Pediatrics       Date:  2019-07-17       Impact factor: 7.124

Review 5.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

6.  Cardiovascular Disease, Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a MicroRNA Connection?

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  Int J Hypertens       Date:  2010-08-04       Impact factor: 2.420

Review 7.  Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management.

Authors:  Angela E Lin; Craig T Basson; Elizabeth Goldmuntz; Pilar L Magoulas; Deborah A McDermott; Donna M McDonald-McGinn; Elspeth McPherson; Colleen A Morris; Jacqueline Noonan; Catherine Nowak; Mary Ella Pierpont; Reed E Pyeritz; Alan F Rope; Elaine Zackai; Barbara R Pober
Journal:  Genet Med       Date:  2008-07       Impact factor: 8.822

8.  Alzheimer's Disease in Down Syndrome.

Authors:  Elizabeth Head; David Powell; Brian T Gold; Frederick A Schmitt
Journal:  Eur J Neurodegener Dis       Date:  2012-12

9.  Lipid profiles of children with Down syndrome compared with their siblings.

Authors:  Tahira Adelekan; Sheela Magge; Justine Shults; Virginia Stallings; Nicolas Stettler
Journal:  Pediatrics       Date:  2012-05-14       Impact factor: 7.124

10.  Atherosclerotic Surrogate Markers in Adults With Down Syndrome: A Case-Control Study.

Authors:  Pedro Parra; Ramón Costa; Diego Real de Asúa; Fernando Moldenhauer; Carmen Suárez
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-06       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.